Brief: Apogee Therapeutics Provides Pipeline Progress And Reports Second Quarter 2025 Financial Results
11/08/2025 12:35
Aug 11 (Reuters) - Apogee Therapeutics Inc APGE.O: APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS APOGEE THERAPEUTICS INC - APEX PHASE 2 PART B OF APG777 READOUT ACCELERATED TO MID-2026 APOGEE THERAPEUTICS - FIRST PATIENT DOSED IN APG279 VERSUS. DUPIXENT TRIAL IN ATOPIC DERMATITIS, WITH READOUT EXPECTED IN 2H 2026 Source text: ID:nGNX8ZcCpw Further company coverage: APGE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)